AMR SVG Icons location

Committed to US-based manufacturing

Over the last several years, we have made significant investments in expanding and modernizing our
US-based manufacturing facilities. This expansion will nearly double our capacity, and allow us to meet demand
well into the future.

Featured image is Chimney Rock State Park, Rutherford County, North Carolina in the United States.

Explore our history

  1. 2023

    American Regent acquires and then merges with HBT Labs, Inc.


    Selenious Acid Injection, USP is launched in a single-dose vial


    Multrys® (trace elements injection*, USP) is launched


    Tralement® (trace elements injection*, USP), the first FDA-approved trace elements injection is introduced

  2. July 2019

    Launch of the first and only 
    FDA-approved Selenious Acid Injection, USP 

    January 2019

    American Regent, Inc. merges into Luitpold Pharmaceuticals, Inc.  The company name is changed to American Regent.


    FDA-approval and launch
    of the first preservative free generic Hydroxyprogesterone Caproate Injection, USP


    American Regent celebrates its 50th Anniversary

  3. 2016

    Launch of ProvayBlue® (methylene blue) Injection, 0.5%, USP*

    *ProvayBlue® is a registered trademark of Provepharm Life Solutions, France


    Injectafer® (ferric carboxymaltose injection)* is FDA Approved. 

    *Injectafer® is a registered trademark of Vifor (International) Inc., Switzerland


    Luitpold acquires PharmaForce, Inc., broadening its line of generic, multisource injectables.

  4. 2005

    Sankyo merges with
    Daiichi Pharmaceutical Company, Ltd.
    to become Daiichi-Sankyo Company, Ltd.


    The name American Regent Laboratories, Inc. was shortened to
    American Regent, Inc.


    Venofer® (iron sucrose injection, USP), now the #1 selling IV iron in the US,* is approved.
    *Source: IMS, NSP Audit Dollars & Units 3 year MAT ending January 2017


    American Regent Laboratories introduces Dexferrum® (iron dextran injection, USP).

  5. 1991

    Sankyo, a Japanese pharmaceutical company, acquires Luitpold and its subsidiary, American Regent Laboratories, Inc.

    Mid 1980s

    Luitpold Pharmaceuticals, Inc.
    acquires American Quinine and transforms the name to
    American Regent Laboratories, Inc.


    A group of dedicated professionals launch our company under the name American Quinine, which provides quality, parenteral products to medical communities within the US and Canada.

Focused on developing excellence in four strategic areas—Reliability, Speed, Flexibility, and Quality


American Regent is an industry leading injectable manufacturer. Our growing business is comprised of mostly generic and branded injectables, as well as leading branded IV iron therapies.

For over 50 years, we've set a higher standard for responsiveness and reliability as a US-based manufacturing company with a short supply chain. Every day we are applying our innovative thinking to respond to customer needs by developing and delivering complex, hard-to-manufacture injectables and drug shortage products. 


Our acquisition of Pharmaforce, Inc. over ten years ago was the first step toward ensuring a consistent, reliable supply of products. Today, between all three of our US manufacturing sites, we have the capability to manufacture over 70 million units annually.

We continue to invest in the expansion and modernization of our US-based manufacturing facilities. These enhancements will allow us to significantly increase output, while creating redundancies across our three manufacturing sites.  This will ensure that we continue to deliver high value for our customers by providing a more reliable, uninterrupted supply of products.



Developing excellence in speed is a critical focus for American Regent, because we believe patients should never have to wait for the medications they need. 

Since we are a US-based manufacturer, we are uniquely positioned to mobilize resources or change production scheduling, so that we can quickly respond to help mitigate shortages, or meet changes in market needs. Our short supply chain allows us to ensure critical medications reach patients quickly.   


Just like speed, the ability to be flexible is critical in the generic injectables market. With demand being so variable, the long lead time of an offshore supply chain makes reacting quickly much more difficult, if not impossible.

American Regent, with its US-based manufacturing and short delivery timelines, has flexibility in production schedulingensuring rapid responses to changes in market demand.


When it comes to quality, our organization focuses on prevention rather than remediation.  We are investing in highly automated manufacturing lines that limit or eliminate human interaction in our sterile filling areas. Finally, our manufacturing facilities are operated by highly trained US labor, using systems that have evolved and been perfected over the last 50 years.

Partner with 
American Regent

American Regent is a leading manufacturer of generic and branded specialty injectables. Given the dynamics of today’s challenging healthcare marketplace …

Learn more

The Latest

  • 2 Jul 2024

    American Regent Introduces Sodium Phosphates Injection, USP; FDA-Approved and “AP” Rated

    Shirley, NY – July 2, 2024:
    American Regent announces the launch and availability of Sodium Phosphates Injection, USP, which is FDA-approved and therapeutically equivalent to Sodium Phosphates.

    Read more

  • 27 Sep 2023

    American Regent Receives 2023 Novaplus Program Excellence Award from Vizient

    Shirley, NY – September 27, 2023:
    American Regent has received a Novaplus Program Excellence Award from Vizient, Inc., the nation’s largest provider-driven health care performance improvement company. The recognition was announced at the 2023 Vizient Connections Summit, held September 18-21 in Las Vegas.

    Read more

Executive Team

Contact Us

Request for Medical Information Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact

By clicking Submit, you confirm that you accept our Privacy Policy and that you agree to your personal contact information being used to contact you and added to our database. If at any time you wish your personal information to be removed from the American Regent® database, please submit a message request to